|Videos|July 2, 2013

Episode 17 - Conclusion: Treatment Advancements and Final Remarks

During this segment, Patricia K. Coyle, MD, Leslie Fish, PharmD, and Gary M. Owens, MD, explain how research has expanded in the neurology field and discuss the therapeutic pipeline for multiple sclerosis (MS) with Dr Fred Lublin.

Dr Coyle discusses the potential of newly developing agents and explains that clinical trials are now testing the efficacy of these products, which is vital when considering data for future clinical guidelines.

However, Dr Owens suggests that expensive costs of treatment and the lack of clinical recommendations or guidelines can cause confusion to clinicians and challenge the future of MS.



Related to this article

CAR T-cell therapy | Image: AdobeStock
In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."